跨性别与性别多元青少年心脏代谢相关诊断的多中心分析:PEDSnet研究
基于PEDSnet 6个站点2009-2019年电子健康记录,将4172例跨性别与性别多元青少年(TGDY)按倾向评分与16648例对照匹配,横断面分析显示TGDY超重/肥胖比值高于对照;在TGDY内部,仅睾酮或睾酮联合GnRHa者血脂异常和肝功能障碍比值高于未用GAHT者,仅睾酮者超重/肥胖和高血压比值更高;雌二醇和单用GnRHa未与更高的心脏代谢诊断比值相关。作者认为需要针对TGDY需求进行筛查和个体化体重管理。
要点
- TGDY超重/肥胖比值高于匹配对照(1.2;95%CI 1.1-1.3)。
- 仅睾酮或联合GnRHa者血脂异常和肝功能障碍比值高于未用GAHT的TGDY。
- 仅睾酮者超重/肥胖和高血压比值高于未用睾酮的TGDY;雌二醇和单用GnRHa未与更高比值相关。
核心结论
- TGDY超重/肥胖比值高于匹配对照,作者认为需要针对TGDY需求进行筛查和个体化体重管理。
研究设计与样本
- 横断面分析,使用PEDSnet多站点数据库2009-2019年电子健康记录。
- TGDY(n=4172)来自6个PEDSnet站点,按8个变量倾向评分匹配对照(n=16648)。
- 采用logistic回归评估TGDY与对照的心脏代谢相关诊断比值,并在TGDY内部单独分析GAHT与结局的关联。
主要发现
- 校正分析中,TGDY超重/肥胖比值高于对照(1.2;95%CI 1.1-1.3)。
- 仅睾酮处方的TGDY血脂异常比值高于未用GAHT的TGDY(1.7;95%CI 1.3-2.3),肝功能障碍比值也更高(1.5;95%CI 1.1-1.9)。
- 睾酮联合GnRHa的TGDY血脂异常比值高于未用GAHT的TGDY(3.7;95%CI 2.1-6.7),肝功能障碍比值也更高(2.5;95%CI 1.4-4.3)。
- 仅睾酮处方的TGDY超重/肥胖比值(1.8;95%CI 1.5-2.1)和高血压比值(1.6;95%CI 1.2-2.2)高于未用睾酮的TGDY。
- 雌二醇和单用GnRHa未与更高的心脏代谢相关诊断比值相关。
临床怎么用
- 作者认为需要针对TGDY需求进行筛查和个体化体重管理。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Studies on cardiometabolic health in transgender and gender-diverse youth (TGDY) are limited to small cohorts. OBJECTIVE: This work aimed to determine the odds of cardiometabolic-related diagnoses in TGDY compared to matched controls in a cross-sectional analysis, using a large, multisite database (PEDSnet). METHODS: Electronic health record data (2009-2019) were used to determine odds of cardiometabolic-related outcomes based on diagnosis, anthropometric, and laboratory data using logistic regression among TGDY youth vs controls. The association of gender-affirming hormone therapy (GAHT) with these outcomes was examined separately among TGDY. TGDY (n = 4172) were extracted from 6 PEDSnet sites and propensity-score matched on 8 variables to controls (n = 16 648). Main outcomes measures included odds of having cardiometabolic-related diagnoses among TGDY compared to matched controls, and among TGDY prescribed GAHT compared to those not prescribed GAHT. RESULTS: In adjusted analyses, TGDY had higher odds of overweight/obesity (1.2; 95% CI, 1.1-1.3) than controls. TGDY with a testosterone prescription alone or in combination with a gonadotropin-releasing hormone agonist (GnRHa) had higher odds of dyslipidemia (1.7; 95% CI, 1.3-2.3 and 3.7; 95% CI, 2.1-6.7, respectively) and liver dysfunction (1.5; 95% CI, 1.1-1.9 and 2.5; 95% CI, 1.4-4.3) than TGDY not prescribed GAHT. TGDY with a testosterone prescription alone had higher odds of overweight/obesity (1.8; 95% CI, 1.5-2.1) and hypertension (1.6 95% CI, 1.2-2.2) than those not prescribed testosterone. Estradiol and GnRHa alone were not associated with greater odds of cardiometabolic-related diagnoses. CONCLUSION: TGDY have increased odds of overweight/obesity compared to matched controls. Screening and tailored weight management, sensitive to the needs of TGDY, are needed.
引用
- Valentine A, Davis S, Furniss A, et al. Multicenter Analysis of Cardiometabolic-related Diagnoses in Transgender and Gender-Diverse Youth: A PEDSnet Study. J Clin Endocrinol Metab. 2022. PMID: 35945152. doi:10.1210/clinem/dgac469
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。